

Corp. Off.: 502, Kanakia Atrium - 2,
Next to Courtyard Marriott Hotel,
Andheri Kurla Road, Andheri (East),
Mumbai - 400 093 (India)
Ph.: + 91 22 61933100 Fax : +91 22 61933114

13th November, 2019

BSE Limited

Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai-400001

National Stock Exchange of India Ltd.

Exchange Plaza, C-1, Block G
Bandra Kurla Complex
Bandra (E), Mumbai-400051

Kind Attn: General Manager-DCS

Scrip Code: 533543

Kind Attn: Head- Listing

Symbol: **BROOKS**

Sub: Disclosure under Regulation 30 & Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015

Dear Sirs,

This has in reference to the regulation mentioned above:



We hereby inform you that the Board of Directors at its meeting held today has, inter alia, approved the Unaudited Financial Results of the Company for the 2nd quarter and half yearly ended 30th September, 2019. The Audit Committee reviewed the Unaudited Financial Results at its meeting held earlier today which have been subjected to a limited review by the Statutory Auditors. The Statement of Unaudited Financial Results, Statement of Assets and Liabilities and Cash Flow Statement as at 30.09.2019 together with the Limited Review Report is attached.

This is for your information and record.

Thanking You,

Yours faithfully

For **BROOKS LABORATORIES LIMITED**



502, Kanakia
Atrium-2, Andheri (E),
Mumbai - 93.

(Jyoti Sancheti)

Company Secretary cum Compliance Officer

Membership No. F9639

Encl.: As Stated Above

Brooks Laboratories Limited

Regd Office: Village Kishanpura, Nalagarh Road, Baddi, Dist. Solan H.P.-174101

CIN NO: L24232HP2002PLC000267

E-mail : investors@brookslabs.net

Website: www.brookslabs.net

Telefax No : +91 1795 236939

Statement of Unaudited Financial Results for the Quarter / Half Year ended 30th September, 2019

(Rs. In Lakhs)

No	Particulars	Quarter Ended			Half Year Ended		Year Ended
		30-Sep-19	30-Jun-19	30-Sep-18	30-Sep-19	30-Sep-18	31.03.2019
		Un-Audited	Un-Audited	Un-Audited	Un-Audited	Un-Audited	Audited
1	Income						
	(a) Revenue from operations	1,414.70	1,682.18	1,410.34	3,096.88	2,477.67	5,503.01
	(b) Other Income	7.28	6.88	5.32	14.16	31.78	287.76
	Total Income	1,421.98	1,689.06	1,415.66	3,111.04	2,509.45	5,790.78
2	Expenses						
	(a) Cost of materials consumed	1,083.45	1,026.92	980.08	2,110.37	1,761.71	4,057.22
	(b) Change in inventories of finished goods, work-in-progress and stock-in-trade	(104.83)	78.00	(13.48)	(26.83)	56.52	(113.62)
	(c) Employees benefits expenses	338.16	318.20	286.66	656.36	557.06	1,216.43
	(d) Finance Costs	79.72	82.82	77.55	162.55	147.07	296.26
	(e) Depreciation and amortization expenses	160.14	157.21	157.01	317.35	319.94	649.96
	(f) Other expenses	291.06	271.60	306.20	562.68	607.49	1,179.30
	Total Expenses	1,847.70	1,934.75	1,794.02	3,782.48	3,449.79	7,285.55
3	Profit/(Loss) before exceptional items and tax	(425.72)	(245.69)	(378.38)	(671.44)	(940.36)	(1,494.77)
4	Exceptional Items	-	-	-	-	-	-
5	Profit/(Loss) from ordinary activities before tax	(425.72)	(245.69)	(378.38)	(671.44)	(940.36)	(1,494.77)
6	Tax Expense:						
	Deferred Tax Liability / (Assets)	(238.02)	127.72	(178.29)	(110.32)	(368.88)	(14.48)
	Short income tax provision for earlier years	-	-	-	-	-	0.23
7	Net Profit/(loss) after tax	(187.70)	(373.41)	(200.09)	(561.12)	(571.48)	(1,480.52)
8	Other Comprehensive Income Items That will not be reclassified into Profit or loss						
	Actuarial loss on Defined Benefit plans (net of tax).	2.69	(2.46)	0.20	0.23	0.41	(7.11)
9	Total Comprehensive income for the period (After tax)	(185.02)	(375.86)	(199.88)	(560.89)	(571.07)	(1,487.63)
10	Paid - up equity share capital of Rs.10 each	1,703.64	1,618.64	1,618.64	1,703.64	1,618.64	1,618.64
11	Reserve excluding Revaluation Reserves as per balance sheet of previous accounting year	8,340.95	8,340.95	9,828.59	8,340.95	9,828.59	9,828.59
12	Earnings per share of Rs.10/- each (not annualised):						
	(a) Basic	(1.12)	(2.31)	(1.24)	(3.34)	(3.53)	(9.15)
	(b) Diluted	(1.12)	(2.31)	(1.24)	(3.34)	(3.53)	(9.15)

For Brooks Laboratories Ltd.

[Signature]
Managing Director

Notes:


- 1 The above unaudited financial results of the Company for the quarter/ half year ended 30th September, 2019 have been reviewed and recommended by the Audit Committee and approved and taken on record by the Board of Directors in their respective meetings held on 13th November, 2019
- 2 The financial results have been prepared in accordance with the Companies (Indian Accounting Standard) Rules, 2015 (Ind AS) prescribed under section 133 of the Companies Act, 2013 and other recognized accounting practices and policies to the extent applicable.
- 3 The Statutory Auditors have carried out Limited Review of the Financial Results and of the Company for the Quarter/Half Year ended September 30, 2019.
- 4 The Company is mainly engaged in the business of "Pharmaceutical Formulations" and there is no other reportable business segment. As the Company's business actually falls within a single primary business segment, the disclosure requirements of Ind-AS - 108 in this regard are not applicable.
- 5 In terms of SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018 as amended ("ICDR Regulations"), the Company has converted 6,37,500 Warrants on 9th July, 2019 and 2,12,500 Warrants on 26th July, 2019 into equivalent number of Equity Shares of face value Rs. 10/- each and at a premium of Rs. 85.50 per share in the Company on receipt of full amount.
- 6 Comparative financial information of the previous quarter and half yearly have been regrouped and reclassified, wherever necessary, to correspond to the figures of the current period presentation.

Place : Mumbai

Date : 13th November, 2019

For and on Behalf of Board


Rajesh Mahajan
Din : 02000634
Managing Director




Brooks Laboratories Limited
Statement of Assets & Liabilities as at September 30, 2019

(Rs. In Lakhs)

Particulars	As at September 30, 2019	As at March 31, 2019
	Unaudited	Audited
A ASSETS		
1 Non Current Assets		
(a) Property, Plant and Equipment	11,617.39	11,717.18
(b) Capital work-in-progress	-	-
(c) Intangible asset	7.00	8.00
(d) Intangible asset under development	39.12	28.91
(e) Investment Property	63.35	63.35
(f) Financial assets		
(i) Investments	2.00	2.00
(ii) Other Financial Assets	146.37	148.19
(g) Income Tax Asset (Net)	495.53	495.19
(h) Deferred tax Asset (Net)	1,201.69	1,091.19
(i) Other Non Current Assets	17.99	44.80
Total Non - Current Assets	13,590.34	13,598.81
2 Current assets		
(a) Inventories	1,008.03	1,005.34
(b) Financial Assets		
(i) Trade receivables	1,599.78	1,141.70
(ii) Cash and Cash Equivalents	108.14	249.85
(iii) Bank Balances other than Cash & cash equivalents	110.52	97.38
(iv) Other Financial Assets	28.60	24.72
(c) Other Current Assets	738.55	677.29
Total Current Assets	3,583.61	3,196.28
TOTAL ASSETS	17,183.96	16,795.09
B EQUITY AND LIABILITIES		
1 Equity		
(a) Equity Share Capital	1,703.64	1,618.64
(b) Other Equity	8,506.82	8,896.45
Total Equity	10,210.46	10,515.09
Liabilities		
2 Non-current liabilities		
(a) Financial Liabilities		
(i) Borrowings	1,240.25	1,386.30
(b) Provisions	170.72	147.52
Total Non - Current Liabilities	1,410.97	1,533.91
3 Current liabilities		
(a) Financial Liabilities		
(i) Borrowings	1,531.46	1,446.88
(ii) Trade Payables		
- Due to micro and small enterprises	492.01	302.96
- Due to Others	2,880.86	2,410.96
(iii) Other Financial Liabilities	463.53	433.77
(b) Other current liabilities	170.79	129.75
(c) Provisions	23.87	21.77
Total Current Liabilities	5,562.52	4,746.10
TOTAL EQUITY AND LIABILITIES	17,183.96	16,795.09

For Brooks Laboratories Limited

Rajesh Mahajan
Din : 02000634
Managing Director



Place : Mumbai
Date : 13th November, 2019

BROOKS LABORATORIES LIMITED
Cash Flow Statement for the period ended 30 September, 2019

(Rs. In Lakhs)

Particulars	Period ended 30 September 2019 Unaudited	Period ended 30 September 2018 Unaudited
A. CASH FLOW FROM OPERATING ACTIVITIES		
Net (loss) / profit before tax	(671.43)	(940.36)
Adjustments for		
Depreciation and amortisation expense	317.35	319.94
Finance cost	162.55	147.07
Interest income	(5.80)	(10.19)
Remeasurement of Defined benefit obligations	0.32	0.56
Dividend from current investments	(0.35)	-
Profit on sale of asset	-	(17.14)
Provision for Expected credit loss	28.73	23.37
Operating profit before working capital changes	(168.64)	(476.74)
Adjustments for changes in working capital:		
Decrease / (increase) in Trade Receivables	(486.45)	(101.36)
Decrease / (increase) in Inventories	(2.70)	122.98
Decrease / (increase) in Other Assets	(34.45)	177.85
Decrease / (increase) in Other Financial Assets	(1.71)	41.90
(Decrease) / Increase in Trade and Other Payables	737.37	52.99
(Decrease) / Increase in Other Financial Liabilities	22.99	(69.92)
(Decrease) / Increase in Other Liabilities	41.04	(34.33)
(Decrease) / Increase in Long term Provisions	23.20	23.17
(Decrease) / Increase in Short term Provisions	2.09	(34.51)
Cash generated from / (used in) operations	132.75	(287.87)
Direct taxes paid (net of refunds received)	(0.34)	(2.04)
Net cash (used in) / from generated from operating activities	132.42	(300.01)
B. CASH FLOW FROM INVESTING ACTIVITIES		
Purchase of property, plant and equipment (including capital work in progress and capital advances)	(226.94)	(56.15)
Proceeds from sale of property, plant and equipment	-	174.52
Loan Received/Repaid	-	(27.91)
Net (investments in)/ proceeds from bank deposits (having original maturity of more than three months)	(13.14)	14.12
Interest received	5.09	10.19
Dividend received	0.35	-
Net cash (used in) / generated from investing activities	(234.64)	114.78
C. CASH FLOW FROM FINANCING ACTIVITIES		
Money received against share warrants	256.26	261.49
Proceeds from borrowings (net)	(45.75)	28.02
Finance costs paid	(171.58)	(147.07)
Net cash (used in) / from financing activities	38.93	142.43
Net decrease in cash and cash equivalents (A+B+C)	(63.29)	(42.79)
Cash and cash equivalents at the beginning of the year	249.85	64.55
Cash and cash equivalents at the end of the year	186.56	21.76

Note:

1. Components of cash and cash equivalents considered only for the purpose of cash flow statement as follows :


Particulars	(Rs. In Lakhs)	
	As at 30 September 2019	As at 30 September 2018
In bank current accounts in Indian rupees	105.22	18.70
Cash on hand	2.92	3.06
	108.14	21.76

Place : Mumbai

Date : 13th November, 2019

For and on Behalf of Board

Rajesh Mahajan
Din : 02000634
Managing Director



SGCO & Co.LLP


Chartered Accountants

Limited Review Report on the Unaudited Financial Results of Brooks Laboratories Limited for the quarter and half year ended September 30, 2019 pursuant to the Regulation 33 of SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015

**The Board of Directors
Brooks Laboratories Limited**

1. We have reviewed the accompanying Statement of Unaudited Financial Results of Brooks Laboratories Limited (The "Company"), for the quarter ended and half year ended on September 30, 2019. This Statement which is the responsibility of the Company's Management and approved by the Board of Directors. Our responsibility is to issue a report on the Statement based on our review.
2. We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement.
3. A review is limited primarily to inquiries of company personnel and analytical procedure applied to financial data and thus provides less assurance than an audit. We have not performed an audit and, accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the Statement has not been prepared in all material respects in accordance with Ind AS and other recognized accounting practices and policies, and has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For SGCO & Co LLP
Chartered Accountants
Firm Reg. No: 112081W / W100184


Suresh Murarka
Partner
Mem No.: 44739
UDIN : 19044739AAAATY2408



Place: Mumbai
Date: 13th November, 2019

4A, Kaledonia,
2nd Floor, Sahar Road,
Near Andheri Station,
Andheri (East),
Mumbai - 400 069.

Tel. +91 22 6625 6363
Fax. +91 22 6625 6364
E-mail: info@sgco.co.in
www.sgco.co.in